spacer
home > ict > autumn 2019 > the practical alternative
PUBLICATIONS
International Clinical Trials

The Practical Alternative






According to the World Alzheimer Report 2015, an estimated 46.8 million people worldwide are living with dementia. This number is predicted to double every 20 years, reaching 74.7 million in 2030 (1). Alzheimer’s disease is the most common cause of dementia, accounting for 60-70% of cases, almost all of which are the sporadic form of the disease rather than the rare familial form (2). The projection that 1 in every 85 people alive in 2050 will have Alzheimer’s disease is a major incentive to find a cure. If a medication that delays the onset of Alzheimer’s by one year is launched by 2020, 9.2 million fewer people would have the disease by 2050 (3).

Over the past 30 years, leading scientists, clinical development teams, and pharmaceutical companies have invested countless hours and billions of dollars investigating treatment options, yet almost all latestage clinical trials of such potential treatments in Alzheimer’s have failed (4-5). Despite the setbacks, all these research efforts have expanded the clinical and biochemical understanding of the disease and its pathology and provided new clues for further studies into this degenerative condition.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Timothy Earle is the Chief Operating Officer and Chief Business Officer at TauRx Therapeutics. Timothy has 30 years’ involvement in the commercial aspects of innovative drug development. He holds a BA (Hons) in Business Studies from the University of Hertfordshire, UK, and an MBA from The Wharton School, University of Pennsylvania, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Team Consulting expands facilities to meet client demand

To meet growing client demand, Team Consulting, a medical device design and development consultancy based in Ickleton, Cambridge, has expanded its facilities to now offer over 5,500 sq ft of lab spaces. Based in the picturesque 13th century Abbey Barns site, the company’s expansion sees the addition of a whole new building with several high-spec lab spaces, design facilities and collaborative workspaces.
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement